The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Maintenance therapy with biweekly cetuximab (C) in the first-line treatment of metastatic colorectal cancer (mCRC): The NORDIC 7.5 study (NCT00660582), by the Nordic Colorectal Cancer Biomodulation Group.
Per Pfeiffer
No relevant relationships to disclose
Halfdan Sorbye
Research Funding - Amgen; Merck; Roche
Camilla Qvortrup
No relevant relationships to disclose
Mia Karlberg
No relevant relationships to disclose
Gisela Naucler
No relevant relationships to disclose
Christian Kersten
No relevant relationships to disclose
Kirsten Vistisen
No relevant relationships to disclose
Birgitta Lindh
No relevant relationships to disclose
Bengt Glimelius
No relevant relationships to disclose